High Purity Rimonabant Weight Loss Powders Rimonabant Hydrochloride CAS 158681-13-1
- الصانع: Dewael
- الفحص المنتج: 99%+
- مظهر خارجي:مسحوق بلوري أبيض.
- مكان المنشأ: الصين
- شهادة: SGS,ISO9001، GMP
- أقل كمية ممكن طلبها: 10ز
- تفاصيل التعبئة: 1 كجم/كيس رقائق,25kg/drum or as your requirements
- موعد التسليم: في غضون 12 ساعة بعد تلقي دفعتك
- شروط الدفع: الاتحاد الغربي, موني جرام,بيتكوين,التحويل المصرفي
- الشحن: EMS,DHL,فيديكس,يو بي إس,TNT وهلم جرا.
- سياسات: إعادة شحن سياسة
- قدرة العرض: 500-600كغم / شهر
High Purity Rimonabant Weight Loss Powders Rimonabant Hydrochloride CAS 158681-13-1
تفاصيل:
Rimonabant hydrochloride
اسم المنتج: Rimonabant hydrochloride
المرادفات: RIMONABANT HYDROCHLORIDE;5-(4-chlorophenyl)-1-(2,4-dichlorophenyl)-4-methyl-n-1-piperidinyl-1h-pyrazole-3-carboxamide monohydrochloride;ACOMPLIA;ACOMPLIA (RIMONABANT;RIMONABANT HCL;rimonabant(Acomplia);RimonabantConsultedStandard;Acomplia, SR141716
CAS: 158681-13-1
MF: C22H21Cl3N4O.ClH
MW: 500.25
Chemical Properties White to Off-White Crystalline Solid
Usage The first of a new class of selective (Cannabinoid-1 (CB-1) receptor antagonists
Usage A brain cannabinoid receptor (CB1) antagonist. Antiobesity agent.
COA:
|
اسم المنتج
|
rimonabant
|
|||
|
CAS لا.
|
168273-06-1 |
Outer Packing
|
1kg/bag | |
|
Production date
|
May 14th. 2018 |
مدة الصلاحية
|
May 13th. 2020 | |
|
Products Standard
|
معيار المؤسسة | |||
|
Items of analysis
|
تخصيص
|
النتائج
|
||
| Assay by (HPLC) | 99%-101% | 99.43% | ||
| Characters/appearance | White to off White powder | يتوافق | ||
| Odor and taste | Odorless | يتوافق | ||
| تعريف | Positive reaction | يتوافق | ||
| Mesh size/sieve analysis | 100% pass 80 mesh | يتوافق | ||
| خسارة في التجفيف | 1% Max | 0.78% | ||
| Water | ≤2.0% | 0.1% | ||
| بقايا على الاشتعال | 01%Max | يتوافق | ||
| Single impurity | 0.1% Max | يتوافق | ||
| Malting point | 272.25 درجة مئوية | يتوافق | ||
| Bolling point | 627 .69 درجة مئوية | يتوافق | ||
| Refractive Index | N20O1.67 | يتوافق | ||
| PH | 50-7.0 | 6.5 | ||
| pK Values | pK. 11.31(Predicted). pK„ 3. 22 (Predicted) | يتوافق | ||
| الذوبانية | Soluble in ethanol (-20 ملغ / مل). DMSO (25 ملغ / مل) .DMF (-20ملغ / مل). and water (< 1 ملغ / مل) | يتوافق | ||
| المعادن الثقيلة | NMT 10ppm | يتوافق | ||
| Microbiological Control | 78cfu/g | 78cfu/g | ||
| Total Plate Count | 1000 cfu/g Max | Negative | ||
| Fungi | <100/ز | Negative | ||
| Salmonella | Negative | Negative | ||
| Coll | negative | negative | ||
|
خاتمة
|
Qualified | |||
Rimonabant Description:
(1). Rimonabant hydrochloride (SR-141716A) is a potent and selective CB1 cannabinoid inverse agonist/antagonist with a Ki of 1.6 نانومتر, minimal affinity for CB2, and and some GPR55 agonist activity. Rimonabant was developed as an anti-obesity drug because of its appetite suppressant activity, but was taken off the market because of side effects of depression and anxiety.
(2). Under development by Sanofi-Aventis, Acomplia (rimonabant) is a selective CB1 endocannabinoid receptor antagonist indicated for the treatment of obesity.
(3). It works by blocking endogenous cannabinoid binding to neuronal CB1 receptors. Activation of these receptors by endoegenous cannabinoids, such as anadamide, increases appetite. It is the most advanced endocannabinoid receptor antagonist in clinical development and offers a novel therapeutic approach to appetite control and weight reduction.
Rimonabant Applications:
(1). Rimonabant has a favorable safety profile and is generally well tolerated. Rimonabant is proving to be a very promising approach for managing two major and preventable risk factors for cardiovascular disease. This review summarizes the available evidence on the clinical efficacy and safety of rimonabant as a potential therapy for obesity and smoking cessation.
(2). Rimonabant hydrochloride also has potential as a treatment for smoking cessation because the endocannabinoid system is involved in the body’s response to tobacco dependence.
———————————————————————————————————————————————————————————————————————————————————————-
اتصل الآن
التعليقات
لا توجد توصيات بعد.